Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
18 "Carcinoma, renal cell"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Loss of Nuclear BAP1 Expression Is Associated with High WHO/ISUP Grade in Clear Cell Renal Cell Carcinoma
Young Chan Wi, Ahrim Moon, Min Jung Jung, Yeseul Kim, Seong Sik Bang, Kiseok Jang, Seung Sam Paik, Su-Jin Shin
J Pathol Transl Med. 2018;52(6):378-385.   Published online October 1, 2018
DOI: https://doi.org/10.4132/jptm.2018.09.21
  • 7,065 View
  • 192 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDF
Background
BRCA1-associated protein 1 (BAP1) mutations are frequently reported in clear cell renal cell carcinoma (ccRCC); however, very few studies have evaluated the role of these mutations in other renal cell carcinoma (RCC) subtypes. Therefore, we analyzed BAP1 protein expression using immunohistochemistry in several RCC subtypes and assessed its relationship with clinicopathological characteristics of patients.
Methods
BAP1 expression was immunohistochemically evaluated in tissue microarray blocks constructed from 371 samples of RCC collected from two medical institutions. BAP1 expression was evaluated based on the extent of nuclear staining in tumor cells, and no expression or expression in < 10% of tumor cells was defined as negative.
Results
Loss of BAP1 expression was observed in ccRCC (56/300, 18.7%), chromophobe RCC (6/26, 23.1%), and clear cell papillary RCC (1/4, 25%), while we failed to detect BAP1 expression loss in papillary RCC, acquired cystic disease-associated RCC, or collecting duct carcinoma. In ccRCC, loss of BAP1 expression was significantly associated with high World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grade (p = .002); however, no significant correlation was observed between loss of BAP1 expression and survival in ccRCC. Loss of BAP1 expression showed no association with prognostic factors in chromophobe RCC.
Conclusions
Loss of BAP1 nuclear expression was observed in both ccRCC and chromophobe RCC. In addition, BAP1 expression loss was associated with poor prognostic factors such as high WHO/ISUP grade in ccRCC.

Citations

Citations to this article as recorded by  
  • Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma
    Ziwei Gui, Juan Du, Nan Wu, Ningning Shen, Zhiqing Yang, Huijun Yang, Xuzhi Wang, Na Zhao, Zixin Zeng, Rong Wei, Wenxia Ma, Chen Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study
    Derek H Liu, Komal A Dani, Sharath S Reddy, Xiaomeng Lei, Natalie L Demirjian, Darryl H Hwang, Bino A Varghese, Suhn Kyong Rhie, Felix Y. Yap, David I. Quinn, Imran Siddiqi, Manju Aron, Ulka Vaishampayan, Haris Zahoor, Steven Y Cen, Inderbir S Gill, Vinay
    Oncology.2023; 101(6): 375.     CrossRef
  • Immunohistochemistry for the diagnosis of renal epithelial neoplasms
    Mahmut Akgul, Sean R Williamson
    Seminars in Diagnostic Pathology.2022; 39(1): 1.     CrossRef
  • BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review
    Shuchi Gulati, Melissa Previtera, Primo N. Lara
    Kidney Cancer.2022; 6(1): 23.     CrossRef
  • Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update
    Ziad M. El-Zaatari, Luan D. Truong
    Biomedicines.2022; 10(3): 657.     CrossRef
  • CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma
    Mounika Angirekula, Sindy Y Chang, Sarah M. Jenkins, Patricia T. Greipp, William R. Sukov, Randolph S. Marks, Kenneth R. Olivier, Stephen D. Cassivi, Anja C Roden
    Cancers.2022; 14(9): 2299.     CrossRef
  • BAP1 in cancer: epigenetic stability and genome integrity
    Sabrina Caporali, Alessio Butera, Ivano Amelio
    Discover Oncology.2022;[Epub]     CrossRef
  • Bioinformatic analysis identifying FGF1 gene as a new prognostic indicator in clear cell Renal Cell Carcinoma
    Xiaoqin Zhang, Ziyue Wang, Zixin Zeng, Ningning Shen, Bin Wang, Yaping Zhang, Honghong Shen, Wei Lu, Rong Wei, Wenxia Ma, Chen Wang
    Cancer Cell International.2021;[Epub]     CrossRef
  • Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis
    Dengyong Xu, Yuzi Xu, Yiming Lv, Fei Wu, Yunlong Liu, Ming Zhu, Dake Chen, Bingjun Bai
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Functional characterisation guides classification of novel BAP1 germline variants
    Jing Han Hong, Siao Ting Chong, Po-Hsien Lee, Jing Tan, Hong Lee Heng, Nur Diana Binte Ishak, Sock Hoai Chan, Bin Tean Teh, Joanne Ngeow
    npj Genomic Medicine.2020;[Epub]     CrossRef
  • Tissue-Based Immunohistochemical Markers for Diagnosis and Classification of Renal Cell Carcinoma
    Liang G Qu, Vaisnavi Thirugnanasundralingam, Damien Bolton, Antonio Finelli, Nathan Lawrentschuk
    Société Internationale d’Urologie Journal.2020; 1(1): 68.     CrossRef
  • Radiogenomics: bridging imaging and genomics
    Zuhir Bodalal, Stefano Trebeschi, Thi Dan Linh Nguyen-Kim, Winnie Schats, Regina Beets-Tan
    Abdominal Radiology.2019; 44(6): 1960.     CrossRef
Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma
Jae Won Joung, Hoon Kyu Oh, Sun Jae Lee, Young Ah Kim, Hyun Jin Jung
J Pathol Transl Med. 2018;52(5):323-330.   Published online August 19, 2018
DOI: https://doi.org/10.4132/jptm.2018.07.21
  • 6,032 View
  • 150 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Background
Intratumoral fibrosis (ITF) is a frequent histologic finding in solid organ tumors. Renal cell carcinoma (RCC) is a highly vascularized tumor with different shapes and degrees of ITF and inflammation. ITF is a poor prognostic factor, especially in breast cancer, and is related to intratumoral necrosis (ITN) and intratumoral inflammation (ITI). However, the significance of ITF in RCC has not been fully studied. In this study, we evaluate the relationships between ITF and other clinicopathologic parameters associated with RCC prognosis.
Methods
ITF was evaluated in 204 clear cell renal cell carcinoma (CCRCC) specimens according to presence and grade of fibrosis, degree of ITI, and presence of ITN. Lysyl oxidase (LOX) expression in tumor cells was also evaluated with clinicopathologic parameters.
Results
Among 204 CCRCC cases, 167 (81.7%) showed ITF, 71 (34.8%) showed ITI, 35 (17.2%) showed ITN, and 111 (54.4%) showed LOX expression. ITF correlated with Fuhrman nuclear grade (p = .046), lymphovascular invasion (LVI) (p = .027), and ITN (p = .036). Patients with ITF had a poor five-year overall survival rate (p = .104).
Conclusions
ITF is related to other poor prognostic factors in CCRCC, such as Fuhrman nuclear grade, ITN, and LVI, but ITF itself had no significant correlation with prognosis of CCRCC.

Citations

Citations to this article as recorded by  
  • New insights into fibrotic signaling in renal cell carcinoma
    Jiao-Yi Chen, Wai-Han Yiu, Patrick Ming-Kuen Tang, Sydney Chi-Wai Tang
    Frontiers in Cell and Developmental Biology.2023;[Epub]     CrossRef
  • Tumor-associated fibrosis impairs the response to immunotherapy
    Angha Naik, Andrew Leask
    Matrix Biology.2023; 119: 125.     CrossRef
  • Decreased renal expression of PAQR5 is associated with the absence of a nephroprotective effect of progesterone in a rat UUO model
    P. A. Abramicheva, D. S. Semenovich, L. D. Zorova, I. B. Pevzner, I. A. Sokolov, V. A. Popkov, E. P. Kazakov, D. B. Zorov, E. Y. Plotnikov
    Scientific Reports.2023;[Epub]     CrossRef
  • Intratumoral fibrosis and patterns of immune infiltration in clear cell renal cell carcinoma
    Songchen Han, Wenbo Yang, Caipeng Qin, Yiqing Du, Mengting Ding, Huaqi Yin, Tao Xu
    BMC Cancer.2022;[Epub]     CrossRef
  • Siglec-F–expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis
    Seungwon Ryu, Jae Woo Shin, Soie Kwon, Jiwon Lee, Yong Chul Kim, Yoe-Sik Bae, Yong-Soo Bae, Dong Ki Kim, Yon Su Kim, Seung Hee Yang, Hye Young Kim
    Journal of Clinical Investigation.2022;[Epub]     CrossRef
  • The atypical sphingosine 1‐phosphate variant, d16:1 S1P, mediates CTGF induction via S1P2 activation in renal cell carcinoma
    Melanie Glueck, Alexander Koch, Robert Brunkhorst, Nerea Ferreiros Bouzas, Sandra Trautmann, Liliana Schaefer, Waltraud Pfeilschifter, Josef Pfeilschifter, Rajkumar Vutukuri
    The FEBS Journal.2022; 289(18): 5670.     CrossRef
  • The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis
    Pramod Mallikarjuna, Yang Zhou, Maréne Landström
    Biomolecules.2022; 12(5): 635.     CrossRef
  • In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer
    Pedro Caetano-Pinto, Nathanil Justian, Maria Dib, Jana Fischer, Maryna Somova, Martin Burchardt, Ingmar Wolff
    International Journal of Molecular Sciences.2022; 23(17): 10177.     CrossRef
  • PD-1 immunobiology in glomerulonephritis and renal cell carcinoma
    Colleen S. Curran, Jeffrey B. Kopp
    BMC Nephrology.2021;[Epub]     CrossRef
  • Intratumoral Fibrosis in Facilitating Renal Cancer Aggressiveness: Underlying Mechanisms and Promising Targets
    Chao Hu, Yufeng Zhao, Xuanchuan Wang, Tongyu Zhu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • What Mediates Fibrosis in the Tumor Microenvironment of Clear Renal Cell Carcinoma
    Wenbo Yang, Caipeng Qin, Jingli Han, Songchen Han, Wenjun Bai, Yiqing Du, Tao Xu
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort
    Pedro Caetano Pinto, Cindy Rönnau, Martin Burchardt, Ingmar Wolff
    Biomedicines.2021; 9(12): 1761.     CrossRef
  • The Significance of Fibrosis Quantification as a Marker in Assessing Pseudo-Capsule Status and Clear Cell Renal Cell Carcinoma Prognosis
    Caipeng Qin, Huaqi Yin, Huixin Liu, Feng Liu, Yiqing Du, Tao Xu
    Diagnostics.2020; 10(11): 895.     CrossRef
  • The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma
    Zuzana Strizova, Jirina Bartunkova, Daniel Smrz
    Cancer Immunology, Immunotherapy.2019; 68(11): 1831.     CrossRef
  • Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma
    Wen-Hao Xu, Yue Xu, Jun Wang, Xi Tian, Junlong Wu, Fang-Ning Wan, Hong-Kai Wang, Yuan-Yuan Qu, Hai-Liang Zhang, Ding-Wei Ye
    Aging.2019; 11(16): 6503.     CrossRef
Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
Cheol Lee, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med. 2017;51(4):359-364.   Published online June 13, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.16
  • 6,697 View
  • 161 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Background
Clear cell renal cell carcinoma (CCRCC) is presumed to be associated with adipogenic differentiation. Histone modification is known to be important for adipogenesis, and the function of histone demethylase plant homeodomain finger 2 (PHF2) has been noted. In addition, PHF2 may act as a tumor suppressor via epigenetic regulation of p53 and is reported to be reduced in colon cancer and stomach cancer tissues. In this study, we examined PHF2 expression in CCRCC specimens by immunohistochemistry.
Methods
We studied 254 CCRCCs and 56 non-neoplastic renal tissues from patients who underwent radical or partial nephrectomy between 2000 and 2003 at the Seoul National University Hospital. Tissue microarray blocks were prepared, and immunohistochemical staining for PHF2 was performed.
Results
Among 254 CCRCC cases, 150 cases (59.1%) showed high expression and 104 cases (40.1%) showed low expression. High expression of PHF2 was significantly correlated with a low Fuhrman nuclear grade (p < .001), smaller tumor size (p < .001), low overall stage (p = .003), longer cancer-specific survival (p = .002), and progression-free survival (p < .001) of the patients. However, it was not an independent prognostic factor in multivariate analysis adjusted for Fuhrman nuclear grade and overall stage.
Conclusions
Our study showed that low expression of PHF2 is associated with aggressiveness and poor prognosis of CCRCC.

Citations

Citations to this article as recorded by  
  • The role of histone methylation in renal cell cancer: an update
    Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu
    Molecular Biology Reports.2023; 50(3): 2735.     CrossRef
  • Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis
    Ying Dong, Hao Hu, Xuan Zhang, Yunkai Zhang, Xin Sun, Hanlin Wang, Weijuan Kan, Min-jia Tan, Hong Shi, Yi Zang, Jia Li
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2
    Peng Luo, Yan-dong Zhang, Feng He, Chang-jun Tong, Kai Liu, He Liu, Shi-zhuang Zhu, Jian-zhou Luo, Bing Yuan
    Scientific Reports.2022;[Epub]     CrossRef
  • Integration of meta-analysis and supervised machine learning for pattern recognition in breast cancer using epigenetic data
    Reza Panahi, Esmaeil Ebrahimie, Ali Niazi, Alireza Afsharifar
    Informatics in Medicine Unlocked.2021; 24: 100629.     CrossRef
  • PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks
    Ignacio Alonso-de Vega, Maria Cristina Paz-Cabrera, Magdalena B Rother, Wouter W Wiegant, Cintia Checa-Rodríguez, Juan Ramón Hernández-Fernaud, Pablo Huertas, Raimundo Freire, Haico van Attikum, Veronique A J Smits
    Nucleic Acids Research.2020; 48(9): 4915.     CrossRef
  • Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities
    Sarder Arifuzzaman, Mst Reshma Khatun, Rabeya Khatun
    Biomedicine & Pharmacotherapy.2020; 129: 110392.     CrossRef
  • Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview
    Tyler S. McCann, Lays M. Sobral, Chelsea Self, Joseph Hsieh, Marybeth Sechler, Paul Jedlicka
    Expert Opinion on Therapeutic Targets.2019; 23(4): 267.     CrossRef
  • MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2
    Yi Fu, Mingyan Liu, Fengxia Li, Li Qian, Ping Zhang, Fengwei Lv, Wenting Cheng, Ruixing Hou
    BioMed Research International.2019; 2019: 1.     CrossRef
  • PHF2 histone demethylase prevents DNA damage and genome instability by controlling cell cycle progression of neural progenitors
    Stella Pappa, Natalia Padilla, Simona Iacobucci, Marta Vicioso, Elena Álvarez de la Campa, Claudia Navarro, Elia Marcos, Xavier de la Cruz, Marian A. Martínez-Balbás
    Proceedings of the National Academy of Sciences.2019; 116(39): 19464.     CrossRef
  • Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia
    Zheng Ge, Yan Gu, Qi Han, Justin Sloane, Qinyu Ge, Goufeng Gao, Jinlong Ma, Huihui Song, Jiaojiao Hu, Baoan Chen, Sinisa Dovat, Chunhua Song
    Epigenomics.2018; 10(1): 59.     CrossRef
Case Studies
Clear Cell Renal Cell Carcinoma with Intratumoral Granulomatous Reaction: A Case Report and Review of the Literature
Hayeon Kim, Jong Wook Kim, Aeree Kim, Hyeyoon Chang
J Pathol Transl Med. 2017;51(3):325-328.   Published online March 14, 2017
DOI: https://doi.org/10.4132/jptm.2016.09.08
  • 7,818 View
  • 115 Download
AbstractAbstract PDF
Granulomatous reaction associated with clear cell renal cell carcinoma (CCRCC) is a rare finding, and only a few cases have been described in the literature. It is postulated to occur due to cancer- related antigenic factors such as cancer cells themselves or soluble tumor antigens shed into the blood. Herein, we describe a case of a 56-year-old male patient diagnosed with CCRCC with intratumoral granulomatous inflammation.
Oncocytic Renal Cell Carcinoma with Tubulopapillary Growth Having a Fat Component
Na Rae Kim, Hyun Yee Cho
J Pathol Transl Med. 2015;49(5):413-417.   Published online July 30, 2015
DOI: https://doi.org/10.4132/jptm.2015.07.01
  • 9,247 View
  • 70 Download
AbstractAbstract PDF
We report a rare case of oncocytic renal cell carcinoma (RCC) with tubulopapillary growth in the background of tuberculous end-stage kidney disease. Histology of the renal mass consisted of oncocytic cells forming solid, thin tubules and rare papillae. The tumor had abundant eosinophilic oncocytic cells containing occasional cytoplasmic Mallory body–like hyaline globules and a tiny focus of clear cells with intervening mature fat. Both the oncocytic cells and clear cells were immunoreactive for a-methylacyl-CoA racemase, vimentin, pancytokeratin, and CD10, and negative for transcription factor E3, CD15, human melanoma black 45, and c-kit. Mallory body–like hyaline globules were positive for CAM 5.2 and periodic acid–Schiff with or without diastase. Ultrastructurally, the tumor cells had abundant cytoplasmic mitochondria. The present case is a rare case of oncocytic RCC with tubulopapillary growth pattern. The case is unique in that the tumor was mixed with fat component, which is not common in RCC and thus can lead to misdiagnosis.
Original Articles
Transglutaminase 2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Min Jee Park, Hae Woon Baek, Ye-Young Rhee, Cheol Lee, Jeong Whan Park, Hwal Woong Kim, Kyung Chul Moon
J Pathol Transl Med. 2015;49(1):37-43.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.10.25
  • 8,528 View
  • 68 Download
  • 15 Web of Science
  • 17 Crossref
AbstractAbstract PDF
Background
A few recent studies have demonstrated a possible role of transglutaminase 2 (TG2) in tumorigenesis or progression of renal cell carcinoma (RCC). The aim of this study was to examine TG2 expression and its clinicopathologic significance in a large number of human clear cell RCCs (CCRCCs). Methods: We analyzed 638 CCRCC patients who underwent partial or radical nephrectomy between 1995 and 2005. The expression of TG2 was determined by immunohistochemistry and categorized into four groups, according to staining intensity: negative (0), mild (1+), moderate (2+), and strong (3+). Results: TG2 staining intensity was negative in 8.5% of CCRCC (n=54), 1+ in 32.6% (n=208), 2+ in 50.5% (n=322), and 3+ in 8.5% (n=54). Strong TG2 expression was correlated with high Fuhrman nuclear grade (p=.011), high T category (p=.049), metastasis (p=.043) and male sex (p<.001) but not with N category.The survival analysis showed a significant association between strong TG2 expression and worse overall and cancer-specific survival (p=.027 and p=.010, respectively). On multivariate analysis, strong TG2 expression was a marginally significant prognostic indicator for Fuhrman nuclear grade and TNM staging (p=.054). Conclusions: Our study is the first to demonstrate the clinicopathologic significance of TG2 expression in a large number of human CCRCC samples. Strong TG2 expression was associated with high nuclear grade and poor prognosis.

Citations

Citations to this article as recorded by  
  • Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma
    Ga-Ram Kim, Joon Hee Kang, Hyeon Joo Kim, Eunji Im, Jinsu Bae, Woo Sun Kwon, Sun Young Rha, Hyun Cheol Chung, Eun Yi Cho, Soo-Youl Kim, Yong-Chul Kim
    Bioorganic Chemistry.2024; 143: 107061.     CrossRef
  • Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target
    Patrizia Malkomes, Ilaria Lunger, Elsie Oppermann, Johannes Lorenz, Sara Fatima Faqar-Uz-Zaman, Jiaoyan Han, Sabrina Bothur, Paul Ziegler, Katrin Bankov, Peter Wild, Wolf Otto Bechstein, Michael A. Rieger
    Cancer Gene Therapy.2023; 30(10): 1346.     CrossRef
  • Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma
    Silvia Muccioli, Valentina Brillo, Tatiana Varanita, Federica Rossin, Elisabetta Zaltron, Angelo Velle, Giorgia Alessio, Beatrice Angi, Filippo Severin, Anna Tosi, Manuela D’Eletto, Luca Occhigrossi, Laura Falasca, Vanessa Checchetto, Roberto Ciaccio, Ame
    Cell Death & Disease.2023;[Epub]     CrossRef
  • The role of transglutaminase 2 in regulation of the balance between autophagy and apoptosis in tumor cells
    Yu. A. Gnennaya, O.  M. Semenov, N. A. Barlev
    Advances in Molecular Oncology.2023; 10(4): 31.     CrossRef
  • Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates
    Sandra Hauser, Paul Sommerfeld, Johanna Wodtke, Christoph Hauser, Paul Schlitterlau, Jens Pietzsch, Reik Löser, Markus Pietsch, Robert Wodtke
    International Journal of Molecular Sciences.2022; 23(9): 4475.     CrossRef
  • The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
    Robert Tempest, Sonia Guarnerio, Rawan Maani, Jamie Cooper, Nicholas Peake
    Cancers.2021; 13(11): 2788.     CrossRef
  • A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
    Soo-Youl Kim, Jeffrey W. Keillor
    International Journal of Molecular Sciences.2020; 21(7): 2493.     CrossRef
  • Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
    Alan A. Azambuja, Paula Engroff, Bruna T. Silva, Roberta C. S. Zorzetti, Fernanda B. Morrone
    International braz j urol.2020; 46(3): 353.     CrossRef
  • Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
    Seon-Hyeong Lee, Joon Hee Kang, Ji Sun Ha, Jae-Seon Lee, Su-Jin Oh, Hyun-Jung Choi, Jaewhan Song, Soo-Youl Kim
    International Journal of Molecular Sciences.2020; 21(14): 5042.     CrossRef
  • Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression
    Burge Ulukan, Ajna Bihorac, Tarik Sipahioglu, Robert Kiraly, Laszlo Fesus, Dilek Telci
    ACS Omega.2020; 5(43): 28273.     CrossRef
  • Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma
    Ayca Ece Nezir, Burge Ulukan, Dilek Telci
    Medical Sciences.2019; 7(2): 24.     CrossRef
  • Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target
    Richard L. Eckert
    Molecular Carcinogenesis.2019; 58(6): 837.     CrossRef
  • Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus
    Nayeon Kim, Joon Hee Kang, Won-Kyu Lee, Seul-Gi Kim, Jae-Seon Lee, Seon-Hyeong Lee, Jong Bae Park, Kyung-Hee Kim, Young-Dae Gong, Kwang Yeon Hwang, Soo-Youl Kim
    Amino Acids.2018; 50(11): 1583.     CrossRef
  • Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
    Seon-Hyeong Lee, Won-Kyu Lee, Nayeon Kim, Joon Kang, Kyung-Hee Kim, Seul-Gi Kim, Jae-Seon Lee, Soohyun Lee, Jongkook Lee, Jungnam Joo, Woo Kwon, Sun Rha, Soo-Youl Kim
    Cancers.2018; 10(11): 455.     CrossRef
  • Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma
    Yesim Bagatur, Ayca Zeynep Ilter Akulke, Ajna Bihorac, Merve Erdem, Dilek Telci
    Cell Adhesion & Migration.2017; : 1.     CrossRef
  • Characterization of clear cell renal cell carcinoma by gene expression profiling
    Bryan J. Thibodeau, Matthew Fulton, Laura E. Fortier, Timothy J. Geddes, Barbara L. Pruetz, Samreen Ahmed, Amy Banes-Berceli, Ping L. Zhang, George D. Wilson, Jason Hafron
    Urologic Oncology: Seminars and Original Investigations.2016; 34(4): 168.e1.     CrossRef
  • Prognostic role of tissue transglutaminase 2 in colon carcinoma
    María Jesús Fernández-Aceñero, Sofía Torres, Irene Garcia-Palmero, Cristina Díaz del Arco, J. Ignacio Casal
    Virchows Archiv.2016; 469(6): 611.     CrossRef
IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
Ji Young Park, Misun Choe, Yuna Kang, Sang Sook Lee
Korean J Pathol. 2014;48(2):108-116.   Published online April 28, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.108
  • 6,899 View
  • 32 Download
  • 4 Crossref
AbstractAbstract PDF
Background

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported as a prognostic biomarker in various cancers. To validate IMP3 as a prognostic biomarker in renal cell carcinoma (RCC), we investigated the expression of IMP3, p53, and Ki-67, and their associations with clinicopathologic outcomes.

Methods

We studied 148 clear cell RCCs (CCRCCs) from patients who underwent radical nephrectomy. The expression levels of IMP3, p53, and Ki-67 were assessed by immunohistochemical staining and the clinical and pathologic parameters were retrospectively reviewed.

Results

Twenty-nine percent of CCRCCs expressed IMP3. Forty-one percent of IMP3-immunopositive tumors developed metastases, while only 11.4% of IMP3-negative tumors developed metastases (p<.001). A Kaplan-Meier curve showed that patients with IMP3-immunopositive tumors had lower metastasis-free survival and cancer-specific survival than did those with IMP3-immunonegative tumors (p<.001 and p<.001, respectively). Expression of high Ki-67 proliferation index was also associated with a higher metastatic rate. In the multivariate Cox regression analysis, pT stage and IMP3-positivity were independently associated with disease-specific survival.

Conclusions

IMP3 is an independent prognostic biomarker for patients with CCRCC to predict metastasis and poor outcome.

Citations

Citations to this article as recorded by  
  • IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas
    Natividad Martin-Morales, Miguel Padial-Molina, Isabel Tovar, Virginea De Araujo Farias, Pedro Hernández-Cortés, Esperanza Ramirez-Moreno, Mercedes Caba-Molina, Justin Davis, Alejandro Carrero Castaño, Jose Mariano Ruiz de Almodovar, Pablo Galindo-Moreno,
    Pathobiology.2023; : 1.     CrossRef
  • circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma
    Yuenan Liu, Kailei Chen, Yi Shou, Sen Li, Jun Wang, Qingyang Zhang, Ziwei Huang, Jiaju Xu, Mingfeng Li, Di Liu, Huageng Liang, Hongmei Yang, Xiaoping Zhang
    Clinical and Translational Medicine.2023;[Epub]     CrossRef
  • Prognostic value of insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer
    Jiannan Liu, Ying Liu, Wenjing Gong, Xiangshuo Kong, Congcong Wang, Shuhua Wang, Aina Liu
    Oncology Letters.2019;[Epub]     CrossRef
  • Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3
    Shuping You, Yun Guan, Weihong Li
    Molecular Medicine Reports.2017;[Epub]     CrossRef
Renal Histologic Parameters Influencing Postoperative Renal Function in Renal Cell Carcinoma Patients
Myoung Ju Koh, Beom Jin Lim, Kyu Hun Choi, Yon Hee Kim, Hyeon Joo Jeong
Korean J Pathol. 2013;47(6):557-562.   Published online December 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.557
  • 5,576 View
  • 41 Download
  • 3 Crossref
AbstractAbstract PDF
Background

Pre-existing non-neoplastic renal diseases or lesions may influence patient renal function after tumor removal. However, its description is often neglected or omitted in pathologic reports. To determine the incidence and clinical significance of non-neoplastic lesions, we retrospectively examined renal tissues obtained during 85 radical nephrectomies for renal cell carcinoma.

Methods

One paraffin-embedded tissue block from each case containing a sufficient amount of non-tumorous renal parenchyma was cut and processed with hematoxylin and eosin and periodic acid-Schiff methods. Non-neoplastic lesions of each histological compartment were semi-quantitatively and quantitatively evaluated.

Results

Among the various histologic lesions found, tubular atrophy, arterial intimal thickening, and glomerulosclerosis were the most common (94.1%, 91.8%, and 88.2%, respectively). Glomerulosclerosis correlated with estimated glomerular filtration rate at the time of surgery, as well as at 1- and 5-years post-surgery (p=.0071), but tubulointerstitial fibrosis or arterial fibrous intimal thickening did not. Post-hoc analysis revealed that glomerulosclerosis of more than 20% predicted post-operative renal function. However, its significance disappeared when gender and age were considered.

Conclusions

In conclusion, non-neoplastic lesions, especially with regard to glomerulosclerosis percentage, should be described in pathology reports to provide additional information on renal function decline.

Citations

Citations to this article as recorded by  
  • Chronic kidney damage pathology score for systematic assessment of the non-neoplastic kidney tissue and prediction of post-operative renal function outcomes
    Yong Jia, Seyed M.M. Poor, Brenden Dufault, Vivian Lu, Jasmir G. Nayak, Deepak K. Pruthi, Ian W. Gibson
    Human Pathology.2022; 124: 76.     CrossRef
  • Value of intravoxel incoherent motion for differential diagnosis of renal tumors
    Qingqiang Zhu, Wenrong Zhu, Jing Ye, Jingtao Wu, Wenxin Chen, Zhihua Hao
    Acta Radiologica.2019; 60(3): 382.     CrossRef
  • Conventional and Papillary Renal Cell Carcinomas and Focal Segmental Glomerulosclerosis in a Nephrectomy
    Firas Al-Delfi, Guillermo A. Herrera
    Pathology Case Reviews.2015; 20(6): 263.     CrossRef
ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients
Cheol Lee, Jeong Whan Park, Ja Hee Suh, Kyung Han Nam, Kyung Chul Moon
Korean J Pathol. 2013;47(5):452-457.   Published online October 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.452
  • 7,185 View
  • 57 Download
  • 27 Crossref
AbstractAbstract PDF
Background

Recently, there have been a few reports of renal cell carcinoma (RCC) cases with anaplastic lymphoma kinase (ALK) gene fusion. In this study, we screened consecutively resected RCCs from a single institution for ALK protein expression by immunohistochemistry, and then we performed fluorescence in situ hybridization to confirm the ALK gene alteration in ALK immunohistochemistry-positive cases.

Methods

We screened 829 RCCs by ALK immunohistochemistry, and performed fluorescence in situ hybridization analysis using ALK dual-color break-apart rearrangement probe. Histological review and additional immunohistochemistry analyses were done in positive cases.

Results

One ALK-positive case was found. Initial diagnosis of this case was papillary RCC type 2. This comprises 0.12% of all RCCs (1/829) and 1.9% of papillary RCCs (1/53). This patient was a 44-year-old male with RCC found during routine health check-up. He was alive without evidence of disease 12 years after surgery. The tumor showed a papillary and tubular pattern, and showed positivity for CD10 (focal), epithelial membrane antigen, cytokeratin 7, pan-cytokeratin, PAX-2, and vimentin.

Conclusions

We found the first RCC case with ALK gene rearrangement in Korean patients by ALK immunohistochemistry among 829 RCCs. This case showed similar histological and immunohistochemical features to those of previous adult cases with ALK rearrangement, and showed relatively good prognosis.

Citations

Citations to this article as recorded by  
  • Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
    Giovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, Mario Roselli, Francesco Torino
    International Journal of Molecular Sciences.2022; 23(7): 3995.     CrossRef
  • Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
    Kiril Trpkov, Sean R. Williamson, Anthony J. Gill, Adebowale J. Adeniran, Abbas Agaimy, Reza Alaghehbandan, Mahul B. Amin, Pedram Argani, Ying-Bei Chen, Liang Cheng, Jonathan I. Epstein, John C. Cheville, Eva Comperat, Isabela Werneck da Cunha, Jennifer B
    Modern Pathology.2021; 34(6): 1167.     CrossRef
  • ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification
    Farshid Siadat, Kiril Trpkov
    Cancers.2020; 12(1): 168.     CrossRef
  • ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology
    Jen-Fan Hang, Hsiao-Jen Chung, Chin-Chen Pan
    Virchows Archiv.2020; 476(6): 921.     CrossRef
  • Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
    Chang Gok Woo, Seok Jung Yun, Seung-Myoung Son, Young Hyun Lim, Ok-Jun Lee
    Yonsei Medical Journal.2020; 61(3): 262.     CrossRef
  • Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers
    Sean R. Williamson, Anthony J. Gill, Pedram Argani, Ying-Bei Chen, Lars Egevad, Glen Kristiansen, David J. Grignon, Ondrej Hes
    American Journal of Surgical Pathology.2020; 44(7): e47.     CrossRef
  • ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217
    Naoto Kuroda, Kiril Trpkov, Yuan Gao, Maria Tretiakova, Yajuan J. Liu, Monika Ulamec, Kengo Takeuchi, Abbas Agaimy, Christopher Przybycin, Cristina Magi-Galluzzi, Soichiro Fushimi, Fumiyoshi Kojima, Malthide Sibony, Jen-Fan Hang, Chin-Chen Pan, Asli Yilma
    Modern Pathology.2020; 33(12): 2564.     CrossRef
  • ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma
    Yiqi Zhu, Ning Liu, Wei Guo, Xiaohong Pu, Hongqian Guo, Weidong Gan, Dongmei Li
    Pathology - Research and Practice.2020; 216(12): 153286.     CrossRef
  • New and emerging renal entities: a perspective post‐WHO 2016 classification
    Kiril Trpkov, Ondřej Hes
    Histopathology.2019; 74(1): 31.     CrossRef
  • Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
    Samer Nassif, Ziad M. El-Zaatari, Michel Attieh, Maya Hijazi, Najla Fakhreddin, Tarek Aridi, Fouad Boulos
    Medicine.2019; 98(32): e16702.     CrossRef
  • Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait
    Xiao-tong Wang, Ru Fang, Sheng-bing Ye, Ru-song Zhang, Rui Li, Xuan Wang, Rong-hao Ji, Zhen-feng Lu, Heng-hui Ma, Xiao-jun Zhou, Qiu-yuan Xia, Qiu Rao
    Pathology - Research and Practice.2019; 215(11): 152651.     CrossRef
  • ALK-rearranged renal cell carcinomas in Polish population
    Adam Gorczynski, Piotr Czapiewski, Aleksandra Korwat, Lukasz Budynko, Monika Prelowska, Krzysztof Okon, Wojciech Biernat
    Pathology - Research and Practice.2019; 215(12): 152669.     CrossRef
  • ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review
    Jing Yang, Lei Dong, Hong Du, Xiu-bo Li, Yan-xiao Liang, Guo-rong Liu
    Diagnostic Pathology.2019;[Epub]     CrossRef
  • Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach
    Reza Alaghehbandan, Delia Perez Montiel, Ana Silvia Luis, Ondrej Hes
    Cancers.2019; 12(1): 85.     CrossRef
  • ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review
    Yohan Bodokh, Damien Ambrosetti, Valérie Kubiniek, Branwel Tibi, Matthieu Durand, Jean Amiel, Morgane Pertuit, Anne Barlier, Florence Pedeutour
    Cancer Genetics.2018; 221: 31.     CrossRef
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma
    Yong Jin Cho, Soo Hee Kim, Eun Kyung Kim, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Sung-Taek Jung, Hyo Song Kim
    BMC Cancer.2018;[Epub]     CrossRef
  • Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
    Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones, Ravi Salgia
    European Urology.2018; 74(1): 124.     CrossRef
  • Genetic analysis and clinicopathological features of ALK‐rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review
    Wenjuan Yu, Yuewei Wang, Yanxia Jiang, Wei Zhang, Yujun Li
    Histopathology.2017; 71(1): 53.     CrossRef
  • A case of anaplastic lymphoma kinase‐positive renal cell carcinoma coincident with Hodgkin lymphoma
    Yuzo Oyama, Haruto Nishida, Takahiro Kusaba, Hiroko Kadowaki, Motoki Arakane, Tsutomu Daa, Dai Watanabe, Yasuyuki Akita, Fuminori Sato, Hiromitsu Mimata, Shigeo Yokoyama
    Pathology International.2017; 67(12): 626.     CrossRef
  • Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas
    An Na Seo, Ghilsuk Yoon, Jae Y. Ro
    Advances in Anatomic Pathology.2017; 24(2): 65.     CrossRef
  • The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications
    Soo Hee Kim, Woo Ick Yang, Yoo Hong Min, Young Hyeh Ko, Sun Och Yoon
    Tumor Biology.2016; 37(2): 2037.     CrossRef
  • New and emerging renal tumour entities
    Naoto Kuroda, Ondřej Hess, Ming Zhou
    Diagnostic Histopathology.2016; 22(2): 47.     CrossRef
  • ALK‐rearranged renal cell carcinomas in children
    Mariana M. Cajaiba, Lawrence J. Jennings, Stephen M. Rohan, Antonio R. Perez‐Atayde, Adrian Marino‐Enriquez, Jonathan A. Fletcher, James I. Geller, Katrin M. C. Leuer, Julia A. Bridge, Elizabeth J. Perlman
    Genes, Chromosomes and Cancer.2016; 55(5): 442.     CrossRef
  • Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene
    Hironori Kusano, Yuki Togashi, Jun Akiba, Fukuko Moriya, Katsuyoshi Baba, Naomi Matsuzaki, Yoshiaki Yuba, Yusuke Shiraishi, Hiroshi Kanamaru, Naoto Kuroda, Seiji Sakata, Kengo Takeuchi, Hirohisa Yano
    American Journal of Surgical Pathology.2016; 40(6): 761.     CrossRef
  • Expanding the spectrum of ALK‐rearranged renal cell carcinomas in children: Identification of a novel HOOK1‐ALK fusion transcript
    Mariana M. Cajaiba, Lawrence J. Jennings, David George, Elizabeth J. Perlman
    Genes, Chromosomes and Cancer.2016; 55(10): 814.     CrossRef
  • TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation
    Paul Scott Thorner, Mary Shago, Paula Marrano, Furqan Shaikh, Gino R. Somers
    Pathology - Research and Practice.2016; 212(10): 937.     CrossRef
  • ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult
    Marie Jeanneau, Valerie Gregoire, Claude Desplechain, Fabienne Escande, Dan Petre Tica, Sebastien Aubert, Xavier Leroy
    Pathology - Research and Practice.2016; 212(11): 1064.     CrossRef
Histologic Variations and Immunohistochemical Features of Metastatic Clear Cell Renal Cell Carcinoma
Cheol Lee, Jeong-Whan Park, Ja Hee Suh, Kyung Han Nam, Kyung Chul Moon
Korean J Pathol. 2013;47(5):426-432.   Published online October 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.426
  • 8,713 View
  • 71 Download
  • 16 Crossref
AbstractAbstract PDF
Background

Due to advancements in treatment of metastatic and advanced renal cell carcinoma (RCC), it has become increasingly important to diagnose metastatic RCC and the specific subtype. In this study, we investigated the diverse histologic features of metastatic clear cell renal cell carcinoma (CCRCC) cases in comparison with corresponding primary lesions.

Methods

We identified 119 metastatic CCRCC cases from 81 corresponding primary lesions diagnosed between 1995 and 2010 and evaluated the diverse histologic and immunohistochemical features of these lesions.

Results

A total of 44 primary lesions (54.3%) had a non-clear cell component in addition to a typical clear cell component. Of the 119 metastatic lesions, 63 lesions (52.9%) contained a non-clear cell component, and 29 metastatic lesions were composed of a non-clear cell component only. Rhabdoid features were the most frequent non-clear cell histology among the metastatic lesions. Metastatic CCRCCs mainly showed positive CD10 and epithelial membrane antigen staining and negative cytokeratin 7 staining.

Conclusions

Metastatic CCRCC commonly showed a variety of histologic features. If there is a difficulty to diagnose metastatic CCRCC due to a variety of histologic features or small biopsy specimen, histologic review of the primary lesion and immunohistochemical analysis can help determine the correct diagnosis.

Citations

Citations to this article as recorded by  
  • Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
    Harrison C. Gottlich, Reza Nabavizadeh, Mihai Dumbrava, Rodrigo Rodrigues Pessoa, Ahmed M. Mahmoud, Ishita Garg, Jacob Orme, Brian A. Costello, John Cheville, Fabrice Lucien
    Kidney Cancer.2023; 7(1): 161.     CrossRef
  • Painful, bleeding fingertip papule
    Jane Gay, Sarah Simpson, Patrick Rush, Alex Holliday
    JAAD Case Reports.2022; 21: 130.     CrossRef
  • Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
    Rory M. Bade, Jennifer L. Schehr, Hamid Emamekhoo, Benjamin K. Gibbs, Tamara S. Rodems, Matthew C. Mannino, Joshua A. Desotelle, Erika Heninger, Charlotte N. Stahlfeld, Jamie M. Sperger, Anupama Singh, Serena K. Wolfe, David J. Niles, Waddah Arafat, John
    Molecular Oncology.2021; 15(9): 2330.     CrossRef
  • Laparoscopic cytoreductive nephrectomy and adrenalectomy for metachronous RCC metastases—Case report
    Bogdan Petrut, Cristina Eliza Bujoreanu, Vasile Vlad Hardo, Adrian Barbos, Bogdan Fetica
    International Journal of Surgery Case Reports.2020; 74: 268.     CrossRef
  • Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?
    Steven L. Chang, Toni K. Choueiri, Lauren C. Harshman
    Urologic Oncology: Seminars and Original Investigations.2019; 37(8): 525.     CrossRef
  • Metastatic TFE3-overexpressing renal clear cell carcinoma with dense granules: a histological, immunohistochemical, and ultrastructural study
    Shoujun Chen, Elba A. Turbat-Herrera, Guillermo A. Herrera, Meghna Chadha, Rodney E. Shackelford, Eric X. Wei
    Ultrastructural Pathology.2018; 42(4): 369.     CrossRef
  • The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
    Rana R. McKay, Dominick Bossé, Wanling Xie, Stephanie A.M. Wankowicz, Abdallah Flaifel, Raphael Brandao, Aly-Khan A. Lalani, Dylan J. Martini, Xiao X. Wei, David A. Braun, Eliezer Van Allen, Daniel Castellano, Guillermo De Velasco, J. Connor Wells, Daniel
    Cancer Immunology Research.2018; 6(7): 758.     CrossRef
  • Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
    Cheol Lee, Bohyun Kim, Boram Song, Kyung Chul Moon
    Journal of Pathology and Translational Medicine.2017; 51(4): 359.     CrossRef
  • Pulmonary metastasectomy from renal cell carcinoma including 3 cases with sarcomatoid component
    Tsuyoshi Ueno, Motohiro Yamashita, Shigeki Sawada, Ryujiro Sugimoto, Noriko Nishijima, Yoshifumi Sugawara, Iku Ninomiya
    General Thoracic and Cardiovascular Surgery.2016; 64(3): 149.     CrossRef
  • Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
    Aleksandra Semeniuk-Wojtaś, Rafał Stec, Cezary Szczylik
    Urologic Oncology: Seminars and Original Investigations.2016; 34(5): 215.     CrossRef
  • Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma
    Sarah P. Psutka, John C. Cheville, Brian A. Costello, Suzanne B. Stewart-Merrill, Christine M. Lohse, Bradley C. Leibovich, Stephen A. Boorjian, R. Houston Thompson
    Urology.2016; 96: 106.     CrossRef
  • The Correlation of Tissue-Based Biomarkers in Primary and Metastatic Renal Cell Carcinoma Lesions: A Tissue Microarray Study
    Sung Han Kim, Weon Seo Park, Eun Young Park, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    The Korean Journal of Urological Oncology.2016; 14(3): 152.     CrossRef
  • Long-term follow-up and clinical course of a rare case of von Hippel-Lindau disease: A case report and review of the literature
    YU ZOU, JINGJING XU, MINMING ZHANG
    Oncology Letters.2016; 11(5): 3273.     CrossRef
  • Genetic alterations in renal cell carcinoma with rhabdoid differentiation
    Carmen M. Perrino, Vishwanathan Hucthagowder, Michael Evenson, Shashikant Kulkarni, Peter A. Humphrey
    Human Pathology.2015; 46(1): 9.     CrossRef
  • High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma
    Cheol Lee, Jeong-Whan Park, Ja Hee Suh, Kyung Chul Moon
    Pathology - Research and Practice.2015; 211(11): 824.     CrossRef
  • A Case of Cutaneous Metastasis from a Clear Cell Renal Cell Carcinoma with an Eosinophilic Cell Component to the Submandibular Region
    Yusuke Amano, Sumie Ohni, Toshiyuki Ishige, Taku Homma, Tsutomu Yamada, Nobuyuki Nishimori, Norimichi Nemoto
    Journal of Nihon University Medical Association.2015; 74(2): 73.     CrossRef
Clear Cell Papillary Renal Cell Carcinoma: A Report of 15 Cases Including Three Cases of Concurrent Other-Type Renal Cell Carcinomas
Jeong Hwan Park, Cheol Lee, Ja Hee Suh, Kyung Chul Moon
Korean J Pathol. 2012;46(6):541-547.   Published online December 26, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.541
  • 7,040 View
  • 57 Download
  • 23 Crossref
AbstractAbstract PDF
Background

Clear cell papillary renal cell carcinoma (CCPRCC) is a recently established subtype of renal epithelial tumor. The aim of this study was to identify the diagnostic criteria of CCPRCC with an emphasis on immunohistochemical studies, and to report three cases with concurrent other-type renal cell carcinoma (RCC).

Methods

A total of 515 RCC patients that consecutively underwent surgical resection at Seoul National University Hospital from 1 January 2010 to 31 December 2011 were screened. Each case was reviewed based on the histologic features and was evaluated immunohistochemically.

Results

A total of 15 CCPRCCs were identified, which composed 2.9% of the total RCCs. The mean age was 52 years, and the average tumor size was 1.65 cm. All 15 cases showed low nuclear grade, no lymph node metastasis and no distant metastasis. The CCPRCCs showed variable architectural patterns including cystic, trabecular, papillary, and acinar. All of the cases showed moderate to intense immunoreactivity for cytokeratin 7 (CK7). CD10 was negative or showed focal weak positivity. Three cases had concurrent other-type RCC, including a clear cell RCC and an acquired cystic disease-associated RCC.

Conclusions

The strong CK7 and negative or focal weak CD10 expression will be useful for the diagnosis of CCPRCC.

Citations

Citations to this article as recorded by  
  • Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios
    Ankur R Sangoi, Harrison Tsai, Lara Harik, Jonathan Mahlow, Maria Tretiakova, Sean R Williamson, Michelle S Hirsch
    Histopathology.2024;[Epub]     CrossRef
  • Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort
    Si Hyun Kim, Jang Hee Han, Seung-hwan Jeong, Hyeong Dong Yuk, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Kyung Chul Moon, Chang Wook Jeong
    BMC Urology.2023;[Epub]     CrossRef
  • Coexistence of multiple clear cell papillary renal cell carcinoma with renal oncocytoma: a case report
    Amine Hermi, Ahmed Saadi, Seif Mokadem, Ahlem Blel, Marouene Chakroun, Mohamed Riadh Ben Slama
    Annals of Medicine & Surgery.2023; 85(5): 2017.     CrossRef
  • Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update
    Ziad M. El-Zaatari, Luan D. Truong
    Biomedicines.2022; 10(3): 657.     CrossRef
  • The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
    Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
    European Urology.2021; 79(4): 468.     CrossRef
  • Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series
    James E. Steward, Sean Q. Kern, Liang Cheng, Ronald S. Boris, Yan Tong, Clint D. Bahler, Timothy A. Masterson, K. Clint Cary, Hristos Kaimakliotis, Thomas Gardner, Chandru P. Sundaram
    Urologic Oncology: Seminars and Original Investigations.2021; 39(6): 370.e21.     CrossRef
  • Clear cell papillary renal cell carcinoma: an update after 15 years
    Sean R. Williamson
    Pathology.2021; 53(1): 109.     CrossRef
  • Clear Cell Papillary Renal Cell Carcinoma
    Jianping Zhao, Eduardo Eyzaguirre
    Archives of Pathology & Laboratory Medicine.2019; 143(9): 1154.     CrossRef
  • Clear cell papillary renal cell carcinoma – An indolent subtype of renal tumor
    Wei-Jen Chen, Chin-Chen Pan, Shu-Huei Shen, Hsiao-Jen Chung, Chih-Chieh Lin, Alex T.L. Lin, Yen-Hwa Chang
    Journal of the Chinese Medical Association.2018; 81(10): 878.     CrossRef
  • Clear cell papillary renal cell carcinoma: A case report and review of the literature
    Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    World Journal of Nephrology.2018; 7(8): 155.     CrossRef
  • Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10‑year retrospective study from two institutions
    Yiqiu Wang, Ying Ding, Jian Wang, Min Gu, Zengjun Wang, Chao Qin, Conghui Han, Hongxia Li, Xia Liu, Pengfei Wu, Guangchao Li
    Oncology Letters.2018;[Epub]     CrossRef
  • A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center
    Maria Rosaria Raspollini, Ilaria Montagnani, Rodolfo Montironi, Liang Cheng, Guido Martignoni, Andrea Minervini, Sergio Serni, Giulio Nicita, Marco Carini, Antonio Lopez-Beltran
    Pathology - Research and Practice.2017; 213(7): 804.     CrossRef
  • Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma
    Hari P. Dhakal, Jesse K. McKenney, Li Yan Khor, Jordan P. Reynolds, Cristina Magi-Galluzzi, Christopher G. Przybycin
    American Journal of Surgical Pathology.2016; 40(2): 141.     CrossRef
  • New and emerging renal tumour entities
    Naoto Kuroda, Ondřej Hess, Ming Zhou
    Diagnostic Histopathology.2016; 22(2): 47.     CrossRef
  • Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features
    Hanan AlSaeid Alshenawy
    Pathology & Oncology Research.2015; 21(4): 893.     CrossRef
  • Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features
    Hanan AlSaeid Alshenawy
    Journal of Microscopy and Ultrastructure.2015; 3(2): 68.     CrossRef
  • Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease
    Manju Aron, Elena Chang, Loren Herrera, Ondrej Hes, Michelle S. Hirsch, Eva Comperat, Philippe Camparo, Priya Rao, Maria Picken, Michal Michal, Rodolfo Montironi, Pheroze Tamboli, Federico Monzon, Mahul B. Amin
    American Journal of Surgical Pathology.2015; 39(7): 873.     CrossRef
  • Papillary or pseudopapillary tumors of the kidney
    Fang-Ming Deng, Max X. Kong, Ming Zhou
    Seminars in Diagnostic Pathology.2015; 32(2): 124.     CrossRef
  • Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
    Mairo L. Diolombi, Liang Cheng, Pedram Argani, Jonathan I. Epstein
    American Journal of Surgical Pathology.2015; 39(12): 1621.     CrossRef
  • Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
    Charles H Lawrie, Erika Larrea, Gorka Larrinaga, Ibai Goicoechea, María Arestin, Marta Fernandez‐Mercado, Ondrej Hes, Francisco Cáceres, Lorea Manterola, José I López
    The Journal of Pathology.2014; 232(1): 32.     CrossRef
  • Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma
    Haijun Zhou, Shaojiang Zheng, Luan D. Truong, Jae Y. Ro, Alberto G. Ayala, Steven S. Shen
    Human Pathology.2014; 45(1): 59.     CrossRef
  • Clear cell papillary renal cell carcinoma: Incidence, morphological features, immunohistochemical profile, and biologic behavior: A single institution study
    Borislav A. Alexiev, Cinthia B. Drachenberg
    Pathology - Research and Practice.2014; 210(4): 234.     CrossRef
  • MRI Phenotype in Renal Cancer
    Naomi Campbell, Andrew B. Rosenkrantz, Ivan Pedrosa
    Topics in Magnetic Resonance Imaging.2014; 23(2): 95.     CrossRef
Case Report
Multifocal Renal Cell Carcinoma of Different Histological Subtypes in Autosomal Dominant Polycystic Kidney Disease
Ki Yong Na, Hyun-Soo Kim, Yong-Koo Park, Sung-Goo Chang, Youn Wha Kim
Korean J Pathol. 2012;46(4):382-386.   Published online August 23, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.4.382
  • 7,937 View
  • 68 Download
  • 10 Crossref
AbstractAbstract PDF

Renal cell carcinoma (RCC) in autosomal dominant polycystic kidney (ADPKD) is rare. To date, 54 cases of RCC in ADPKD have been reported. Among these, only 2 cases have different histologic types of RCC. Here we describe a 45-year-old man who received radical nephrectomy for multifocal RCC with synchronous papillary and clear cell histology in ADPKD and chronic renal failure under regular hemodialysis. The case reported herein is another example of the rare pathological finding of RCC arising in a patient with ADPKD.

Citations

Citations to this article as recorded by  
  • The Importance of Genetic Testing in the Differential Diagnosis of Atypical TSC2-PKD1 Contiguous Gene Syndrome—Case Series
    Petronella Orosz, Zita Kollák, Ákos Pethő, András Fogarasi, György Reusz, Kinga Hadzsiev, Tamás Szabó
    Children.2023; 10(3): 420.     CrossRef
  • Renal Cell Carcinoma in the Background of Autosomal Dominant Polycystic Kidney Disease: Report of Two Cases and Review of Literature
    Poorva Vias, Shikha Goyal, Renu Madan, Nandita Kakkar, Ridhi Sood, Kannan Periasamy, Rajender Kumar
    Indian Journal of Medical and Paediatric Oncology.2023;[Epub]     CrossRef
  • Autosomal dominant polycystic kidney disease coming up with an unusual presentation of renal cell carcinoma on its first encounter
    Asma Shoukat Masumdar, Anitha Padmanabhan, Nitin Gadgil, Gargi Padalkar
    Indian Journal of Pathology and Oncology.2023; 10(4): 417.     CrossRef
  • Sarcomatoid renal cell carcinoma with autosomal dominant polycystic kidney disease: a case report and literature review
    Yuji Hakozaki, Kiyotaka Uchiyama, Akane Yanai, Daisuke Yamada, Yuka Kamijo, Yoshitaka Ishibashi
    CEN Case Reports.2021; 10(2): 199.     CrossRef
  • CT and MRI findings of cystic renal cell carcinoma: comparison with cystic collecting duct carcinoma
    Qingqiang Zhu, Jun Ling, Jing Ye, Wenrong Zhu, Jingtao Wu, Wenxin Chen
    Cancer Imaging.2021;[Epub]     CrossRef
  • Incidental occurrence of papillary renal cell carcinoma in the native kidney with autosomal dominant polycystic kidney disease after renal transplantation: A case report
    Mahmoud Abbas, Melanie Pätzel, Angelika Thurn, Olaf Brinkmann, Olaf Bettendorf
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Xp11.2 translocation renal cell carcinoma in the autosomal dominant polycystic kidney disease patient with preserved renal function
    Hyuk Huh, Hyung Ah Jo, YongJin Yi, Seung Hyup Kim, Kyung Chul Moon, Curie Ahn, Hayne Cho Park
    The Korean Journal of Internal Medicine.2017; 32(6): 1108.     CrossRef
  • The Association between Autosomal Dominant Polycystic Kidney Disease and Renal Cell Carcinoma
    Chase C. Hansen, Michael Derrick, Irfan Warriach, James Thomas Cammack, James Thomas Cammack, Werner de Riese
    Open Journal of Urology.2015; 05(06): 84.     CrossRef
  • The MSCT and MRI findings of collecting duct carcinoma
    Q. Zhu, J. Wu, Z. Wang, W. Zhu, W. Chen, S. Wang
    Clinical Radiology.2013; 68(10): 1002.     CrossRef
  • Thyroid-like follicular carcinoma of the kidney in a patient with nephrolithiasis and polycystic kidney disease: a case report
    Metka Volavšek, Margareta Strojan-Fležar, Gregor Mikuz
    Diagnostic Pathology.2013;[Epub]     CrossRef
Original Articles
Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Ji Won Lee, Jeong Hwan Park, Ja Hee Suh, Kyung Han Nam, Ji-Young Choe, Hae Yoen Jung, Ji Yoen Chae, Kyung Chul Moon
Korean J Pathol. 2012;46(3):237-245.   Published online June 22, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.237
  • 7,327 View
  • 34 Download
  • 16 Crossref
AbstractAbstract PDF
Background

The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.

Methods

Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.

Results

Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.

Conclusions

This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.

Citations

Citations to this article as recorded by  
  • Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition
    Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • The tumor microenvironment and immune targeting therapy in pediatric renal tumors
    Amy B. Hont, Benoit Dumont, Kathryn S. Sutton, John Anderson, Alex Kentsis, Jarno Drost, Andrew L. Hong, Arnauld Verschuur
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT
    Priyanka F. Karmokar, Nader H. Moniri
    Cancer Cell International.2023;[Epub]     CrossRef
  • Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways
    Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao, Ronghua Dai
    Journal of Ethnopharmacology.2022; 284: 114740.     CrossRef
  • Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration
    Yu-Sang Li, Jian Zhang, Gui-Hua Tian, Hong-Cai Shang, He-Bin Tang
    Journal of Ethnopharmacology.2021; 268: 113547.     CrossRef
  • Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
    Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral
    European Archives of Oto-Rhino-Laryngology.2018; 275(9): 2341.     CrossRef
  • Retrospective evaluation of COX‐2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy
    S. Carvalho, A. L. Stoll, S. L. Priestnall, A. Suarez‐Bonnet, K. Rassnick, S. Lynch, I. Schoepper, G. Romanelli, P. Buracco, M. Atherton, E. M. de Merlo, A. Lara‐Garcia
    Veterinary and Comparative Oncology.2017; 15(4): 1280.     CrossRef
  • Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
    Arancha Cebrián, Teresa Gómez del Pulgar, María José Méndez-Vidal, María Luisa Gonzálvez, Nuria Lainez, Daniel Castellano, Iciar García-Carbonero, Emilio Esteban, Maria Isabel Sáez, Rosa Villatoro, Cristina Suárez, Alfredo Carrato, Javier Munárriz-Ferránd
    Scientific Reports.2017;[Epub]     CrossRef
  • COX-2 expression in ovarian cancer: an updated meta-analysis
    Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao, Yan Jin
    Oncotarget.2017; 8(50): 88152.     CrossRef
  • COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis
    Hedieh Moradi Tabriz, Marzieh Mirzaalizadeh, Shahram Gooran, Farzaneh Niki, Maryam Jabri
    Asian Pacific Journal of Cancer Prevention.2016; 17(2): 535.     CrossRef
  • Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma
    Kosuke Saito, Eri Arai, Keiko Maekawa, Masaki Ishikawa, Hiroyuki Fujimoto, Ryo Taguchi, Kenji Matsumoto, Yae Kanai, Yoshiro Saito
    Scientific Reports.2016;[Epub]     CrossRef
  • Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma
    Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
    Melanoma Research.2016; 26(5): 448.     CrossRef
  • New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
    Honor J. Hugo, C. Saunders, R. G. Ramsay, E. W. Thompson
    Journal of Mammary Gland Biology and Neoplasia.2015; 20(3-4): 109.     CrossRef
  • The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy
    Katarzyna Kaminska, Cezary Szczylik, Fei Lian, Anna M Czarnecka
    Future Oncology.2014; 10(14): 2177.     CrossRef
  • Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications
    Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły
    Cancer Letters.2013; 341(2): 111.     CrossRef
  • Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis
    Zhe Wang, Maolin He, Zengming Xiao, Hao Wu, Yang Wu, Dominique Heymann
    PLoS ONE.2013; 8(12): e82907.     CrossRef
Prognostic Significance and Nature of Rhabdoid Features in Renal Cell Carcinoma.
Misun Choe, Ji Young Park, Ilseon Hwang, Sang Pyo Kim
Korean J Pathol. 2011;45(4):371-378.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.4.371
  • 3,165 View
  • 22 Download
AbstractAbstract PDF
BACKGROUND
Recent reports have indicated that renal cell carcinoma (RCC) with rhabdoid features follows an aggressive clinical course. We investigated the prognostic significance and nature of the rhabdoid component.
METHODS
We retrospectively analyzed the incidence and clinicopathologic characteristics of RCC with rhabdoid features in 174 radical nephrectomy cases. The specimens were examined histologically and immunohistochemically.
RESULTS
Twelve of the 174 RCC cases (6.9%) showed rhabdoid features. Histologically, all the tumors with rhabdoid features were of the clear cell type. The presence of rhabdoid features was significantly associated with higher Fuhrman's nuclear grade and higher pathologic tumor stage at presentation. Among the 12 patients who showed the rhabdoid component, nine (75%) developed metastasis and seven (58.3%) died of disease-related causes. The presence of rhabdoid features was independently associated with metastasis and disease-related mortality. The rhabdoid cells were positive for vimentin; variably positive for pan-cytokeratin, epithelial membrane antigen, and CD10; and negative for cytokeratin 7, smooth muscle actin, desmin, E-cadherin, and c-Kit. No case showed loss of integrase interactor-1; one was p53 positive, and five were insulin-like growth factor mRNA binding protein 3 positive. The Ki-67 labeling index was 1-25% (mean, 5.5%).
CONCLUSIONS
The rhabdoid component is an independent prognostic factor for metastasis of RCC; therefore, identification of this component is critical.
Case Report
Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Aggressive Behavior: An Unusual Renal Epithelial Neoplasm: A Case Report.
Ji Hye Lee, Mee Hye Oh, Hyun Deuk Cho, Young Sik Kim
Korean J Pathol. 2010;44(2):211-215.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.2.211
  • 3,242 View
  • 20 Download
  • 1 Crossref
AbstractAbstract PDF
Mucinous tubular and spindle cell carcinoma is a rare low-grade renal cell carcinoma, which was first described as a new entity in the World Health Organization 2004 classification. We report here on a case of this tumor with very unusual aggressive behavior. A 73-year-old man presented with gross hematuria. A computed tomography scan demonstrated a 5 cm sized low density mass in the left kidney. The radical nephrectomy specimen grossly showed a well demarcated tumor confined to the renal parenchyma. Histologically, the tumor consisted of elongated tubules or trabeculae of oval to cuboidal cells with a low nuclear grade, and these tubules/trabeculae were separated by abundant acidic mucinous stroma. In some areas, spindle cell components were mixed with parallel tubules. Neither significant atypia nor mitosis was seen. The patient developed multiple metastatic pulmonary nodules 2 months later. Four months after the surgery, the left supraclavicular, right hilar and right subcarinal lymph nodes were also enlarged by metastasis. The patient died of respiratory failure 13 months after the operation.

Citations

Citations to this article as recorded by  
  • Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of low-grade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma
    Kvetoslava Peckova, Petr Martinek, Maris Sperga, Delia Perez Montiel, Ondrej Daum, Pavla Rotterova, Kristýna Kalusová, Milan Hora, Kristýna Pivovarcikova, Boris Rychly, Semir Vranic, Whitney Davidson, Josef Vodicka, Magdaléna Dubová, Michal Michal, Ondrej
    Annals of Diagnostic Pathology.2015; 19(4): 226.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine